BPS 2022

GIPR antagonist antibodies conjugated to GLP-1 peptide are multispecific molecules that decrease weight in obese mice & monkeys

Les Miranda

Executive Director, R&D & CMC Operations, Amgen

ABSTRACT

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) regulate glucose and energy homeostasis. Targeting both pathways with GIP receptor (GIPR) antagonist antibody (GIPR-Ab) and GLP-1 receptor (GLP-1R) agonist, by generating GIPR-Ab/GLP-1 multispecific molecules, is an approach for treating obesity and its comorbidities. In mice and monkeys, these multispecific molecules reduce body weight (BW) and improve many metabolic parameters. Overall, these GIPR-
Ab/GLP-1 molecules promote BW loss, and they may be used for treating obesity.

BIO

Over 20 years of Research and Operations experience in developing innovative therapeutic candidates spanning RNA, biologics, peptide, and small molecule modalities focusing on the areas of metabolic disease, neurobiology, hematology, oncology, and inflammation; leading to the filing of >19 Investigational New Drug (IND) applications to advance life-changing medicines for patients, >50 peer-reviewed top-tier publications, and an inventor on 30 public domain patent applications including AMG 133. Extensive scientific experience in diverse therapeutic modality & technology platforms for peptides, oligonucleotides (RNA), biologics, T-cell engagers, multi-specifics, antibody-peptide conjugation, ADCs, and small molecules involving RNA-based screening technologies, analytical chemistry, structural biology, computational chemistry, laboratory automation, and data science. Strong executive experience and presence in facility and staff management (>75 FTEs, >$25M budget); organizational transformation; early pipeline review; product & technology licensing;, acquisitions; and venture investment. Experienced public speaker at international scientific events, and co-chair for the Gordon Research Conference (GRC), Chemistry & Biology of Peptides, and the 27th American Peptide Symposium.

Information for BPS Presenters

The Boulder Peptide Foundation was established to further the science and knowledge of peptide technology to develop novel therapeutics, biomaterials, medical diagnostics and other beneficial uses for mankind. As part of this goal we run several programs to support career advancement, seminars and educational events. Join us on our mission to expand the applications of peptide science.

Information for BPS Presenters

The purpose of the Boulder Peptide Symposium is to encourage sharing of information related to peptide therapeutic development with an emphasis on the technical, scientific and regulatory aspects of the pharmaceutical development. Presentations that demonstrate original thinking or share experiences from case studies in product development shall receive priority over others.

The Boulder Peptide Symposium offers multiple opportunities for participants to present.

Oral Presentations in Scientific Sessions

The session topics for Scientific Program are Peptides in the Clinic, Drug Delivery, Chemistry of Complex Peptides, Spotlight on Discovery, and Peptide Showcase. Abstracts may be submitted via the Apply to Present page on the website. Submissions will be reviewed by the Scientific Advisory Board on a monthly basis and the speaker will be notified of a decision.

Presentation length: Format is 25-30 minutes slide presentation with 5-10 minutes for Q&A, with the exception of Peptide Showcase talks which are 10 minute slide presentations with 5 minutes for Q&A. Please confirm with your session chair to confirm the exact presentation length.

Invited Speakers: Speakers are requested to supply their presentation details 30 days after receiving an invitation to present.

Program Book Deadline: Final abstract and title must be provided no later than September 1st. No changes to the program are possible after this date.

Presentation Format: Oral presenters please provide your presentation slides to the A/V table on the day of your presentation.

Lodging: All speakers are requested to reserve their own room. Discount rates at the conference hotel are available until August 16th.

Registration: All speakers, excluding sponsored presentation speakers, receive a complimentary registration upon approval of the abstract.

Peptide Showcase Description

The Peptide Showcase is an opportunity for an individual or company to “showcase” new ideas, technology and pipeline assets. Priority shall be given to presentations from biotech and startup companies. Service providers and vendors are not eligible. Speakers in the session receive a complimentary event registration.

Posters

Posters can be presented on any topic relevant to peptides including original research, innovative products and technologies.

Eligibility- Any attendee (from academia, industry, biotech or vendor/sponsor) can present a poster. The presentation must contain original scientific thinking. To submit a poster go to the Submit a Poster link from the meeting menu. All submissions are reviewed on a rolling basis and will be notified of approval. September 1st is the last day to submit a poster abstract. Approved posters are published on the BPF website.

A 30 ” x 40″ board shall be provided with thumb tacks. Board will be on an easel and can be rotated for either landscape or portrait formats. Once you apply for a poster, you will get email confirmation that your poster was accepted. The poster session and number assignments will be emailed one week before the Symposium.

Poster boards shall be available for display from 8am to 8pm the day of your assigned poster session. See the program agenda for the poster session schedule.

Public Release

Every presentation at the Boulder Peptide Symposium is automatically recorded. Speakers are required to give consent for sharing of the presentation video with the peptide community.

Refund Policy - Terms and Conditions - Privacy Policy